We are live on ! Find out more
ACM

ADAR1 Capital Management Portfolio holdings

AUM $2.19B
1-Year Est. Return 374.99%
This Fund
S&P 500
This Quarter Est. Return
+8.25%
1 Year Est. Return
+374.99%
3 Year Est. Return
–
5 Year Est. Return
–
10 Year Est. Return
–
AUM
$1.7B
AUM Growth
+$337M
Cap. Flow
+$308M
Cap. Flow %
18.12%
Top 10 Hldgs %
39.64%
Holding
351
New
78
Increased
102
Reduced
60
Closed
41

Top Buys

Rank Stock Value
1
BEAM icon
Beam Therapeutics
BEAM
+$40.1M
2
CRNX icon
Crinetics Pharmaceuticals
CRNX
+$37.1M
3
DNLI icon
Denali Therapeutics
DNLI
+$36.2M
4
INSP icon
Inspire Medical Systems
INSP
+$27.3M
5
VIR icon
Vir Biotechnology
VIR
+$21.9M

Top Sells

Rank Stock Value
1
RNAM
Avidity Biosciences
RNAM
+$39.4M
2
RAPT
RAPT Therapeutics
RAPT
+$17.3M
3
CDTX
Cidara Therapeutics
CDTX
+$13.2M
4
FULC icon
Fulcrum Therapeutics
FULC
+$10.4M
5
ABUS icon
Arbutus Biopharma
ABUS
+$9.98M

Sector Composition

Rank Sector Weight
1 Healthcare 88.42%
2 Miscellaneous 9.68%
3 Financials 1.51%
4 Technology 0.08%
5 Industrials 0.08%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
CCIIU
126
Cohen Circle Acquisition Corp II Unit
CCIIU
$1.55M 0.09%
150,000
– –
RCKT icon
127
Rocket Pharmaceuticals
RCKT
$424M
$1.55M 0.09%
432,500
-43,300
-9% -$172K
SUPN icon
128
Supernus Pharmaceuticals
SUPN
$2.54B
$1.53M 0.09%
29,642
-100
-0.3% -$5.09K
CNTA
129
DELISTED
Centessa Pharmaceuticals
CNTA
$1.53M 0.09%
38,566
– –
FOLD
130
DELISTED
Amicus Therapeutics
FOLD
$1.52M 0.09%
+105,000
New +$1.51M
MAZE
131
Maze Therapeutics
MAZE
$1.52B
$1.5M 0.09%
50,095
-129,437
-72% -$5.71M
UNH icon
132
UnitedHealth
UNH
$353B
$1.49M 0.09%
+5,501
New +$1.64M
ADGM
133
Adagio Medical Holdings
ADGM
$11.3M
$1.39M 0.08%
1,205,447
+45,833
+4% +$46.5K
FWRD icon
134
Forward Air
FWRD
$574M
$1.31M 0.08%
78,241
+51,606
+194% +$1.26M
SXT icon
135
Sensient Technologies
SXT
$5.75B
$1.3M 0.08%
+15,000
New +$1.4M
KNSA icon
136
Kiniksa Pharmaceuticals
KNSA
$6.09B
$1.3M 0.08%
26,913
-1,815
-6% -$80.4K
CRVS icon
137
Corvus Pharmaceuticals
CRVS
$1.19B
$1.29M 0.08%
87,901
-377,974
-81% -$6.03M
MSLE
138
Satellos Bioscience
MSLE
$184M
$1.25M 0.07%
+222,555
New +$2.19M
QURE icon
139
uniQure
QURE
$3.38B
$1.25M 0.07%
76,206
-158,949
-68% -$3.22M
NVO
140
Novo Nordisk
NVO
$202B
$1.21M 0.07%
+33,000
New +$1.56M
PMN icon
141
ProMIS Neurosciences
PMN
$124M
$1.21M 0.07%
+95,350
New +$1.42M
LXRX icon
142
Lexicon Pharmaceuticals
LXRX
$1.02B
$1.17M 0.07%
+750,000
New +$1.09M
SDGR icon
143
Schrodinger
SDGR
$1.47B
$1.15M 0.07%
+101,500
New +$1.4M
KPTI icon
144
CALL
Karyopharm Therapeutics
KPTI
$42.4M
$1.14M 0.07%
+205,200
New +$1.56M
XNCR icon
145
Xencor
XNCR
$1.94B
$1.13M 0.07%
93,665
+37,500
+67% +$465K
OABI icon
146
OmniAb
OABI
$650M
$1.11M 0.07%
705,190
+3,000
+0.4% +$5.41K
FDMT icon
147
4D Molecular Therapeutics
FDMT
$810M
$1.09M 0.06%
116,712
– –
KROS icon
148
Keros Therapeutics
KROS
$219M
$1.07M 0.06%
97,318
+78,467
+416% +$1.21M
DAWN
149
DELISTED
Day One Biopharmaceuticals
DAWN
$1.07M 0.06%
+49,923
New +$703K
BMY icon
150
Bristol-Myers Squibb
BMY
$136B
$1.06M 0.06%
17,500
-2,500
-13% -$146K
4 5
6
7 8

Similar funds

GAMH
Greenwoods Asset Management (HK) Hong Kong $2.19B AUM 50.16% 1-Year Est. Return
RCAG
Rehmann Capital Advisory Group Lansing, Michigan $2.18B AUM 23.73% 1-Year Est. Return
AF
Advisornet Financial Minnetonka, Minnesota $2.19B AUM 21.28% 1-Year Est. Return
AWM
Angeles Wealth Management Santa Monica, California $2.19B AUM 23.13% 1-Year Est. Return
TCM
Traynor Capital Management Malvern, Pennsylvania $2.18B AUM 62.36% 1-Year Est. Return
WRBC
W.R. Berkley Corp Greenwich, Connecticut $2.18B AUM 13.58% 1-Year Est. Return
IAN
Integrated Advisors Network Dallas, Texas $2.18B AUM 30.3% 1-Year Est. Return
BOI
Bank of Italy Rome, Italy $2.2B AUM 1.53% 1-Year Est. Return

ADAR1 Capital Management's Q1 2026 Portfolio in Review

As of Q1 2026, ADAR1 Capital Management held 351 positions worth $1.7B, up 25% from $1.36B the previous quarter. Its ten largest holdings account for 40% of the portfolio.

ADAR1 Capital Management deployed $308M of net new capital in Q1 2026, opening 78 new positions and adding to 102 existing holdings. Its largest new stake was Beam Therapeutics: 1,446,375 shares worth $34.5M.

By sector, the portfolio is most concentrated in Healthcare at 88% of assets, down from 89% a quarter earlier, followed by Miscellaneous and Financials.

On the sell side, the largest reduction was Fulcrum Therapeutics, an estimated $10.4M trimmed.

  • ADAR1 Capital Management's largest Q1 2026 buy was Beam Therapeutics: 1,446,375 shares worth $34.5M.
  • ADAR1 Capital Management added most to Crinetics Pharmaceuticals in Q1 2026, an estimated $37.1M increase.
  • ADAR1 Capital Management's biggest Q1 2026 reduction was Fulcrum Therapeutics, cutting an estimated $10.4M.
  • ADAR1 Capital Management fully exited Avidity Biosciences in Q1 2026, selling an estimated $39.4M.
  • ADAR1 Capital Management's ten largest holdings make up 40% of its $1.7B portfolio in Q1 2026.
  • ADAR1 Capital Management opened 78 new positions and closed 41 in Q1 2026.
  • ADAR1 Capital Management's portfolio value rose 25% quarter-over-quarter to $1.7B.

Based on ADAR1 Capital Management's 13F filing for Q1 2026, filed 18 May 2026.